Erasca, Inc. (ERAS) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Erasca, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 15.44 at 7:15 am ET, low 14.54 at 12:15 pm ET.
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
the bull case· 3
5
disclosed supplier and customer ties in SEC filings indicating integrated commercial relationships
sec filingsedgar258
managers reporting a position in filings showing broad institutional ownership
13fJun 30 '26+5.18%
change in shares held by the largest reporting managers reflecting net accumulation
13fJun 30 '26the bear case· 2
8 of 8
recent reports where the move came in under the options-implied range indicating muted reaction
earnings historyimplied vs realized6 of 23
largest reporting managers cut their stake in the latest quarter signaling portfolio trimming
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 12 '26 report. Not a forecast, not advice.
Of the 6 companies Erasca, Inc. moves with most closely, none share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
257 managers report a position worth $5.3B between them, and 28 of them hold 80% of it.
tall tick = annual report · 1 on record
ERAS (Erasca, Inc.) has 4 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.